Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 7/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.35 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.34 |
| ▸ | PNP | P00491 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.34 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25867818 | 0.88 | PNP (0.39) | ADORA3PNPLMNATP53HTT | |
| SCHEMBL24336457 | 0.79 | PNP (0.39) | NT5EADORA3RNASELPNPLMNA | |
| SCHEMBL12214180 | 0.78 | AHCY (0.41) | NT5EADORA3PNPLMNATP53 | |
| SCHEMBL25659855 | 0.78 | AHCY (0.45) | NT5EADORA3PNPLMNATP53 | |
| SCHEMBL21709653 | 0.78 | AHCY (0.40) | NT5EADORA3PNPLMNATP53 | |
| SCHEMBL13581562 | 0.76 | AHCY (0.42) | NT5EADORA3PNPLMNATP53 | |
| SCHEMBL22855175 | 0.76 | AHCY (0.47) | NT5EADORA3PNPLMNATP53 | |
| SCHEMBL2524440 | 0.76 | PDE4D (0.53) | NT5EADORA3PNPLMNATP53 | |
| SCHEMBL2520516 | 0.76 | AHCY (0.47) | NT5EADORA3PNPLMNATP53 | |
| SCHEMBL22939391 | 0.76 | CHKA (0.44) | NT5EADORA3LMNAADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226093-A1 | ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | BRII BIOSCIENCES, INC. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226093-A1 | ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | ADAR, ADA, ADORA2A | NT5E 50/4885ADORA3 8/4885RNASEL 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.